79 related articles for article (PubMed ID: 334188)
1. [New antihypertensive agent of the imidazoline series: 5-fluoro-methyl-imidazolidinylidene-benzamine-monohydrochloride (flutonidin)].
Brunner H; Djawan S; Dorda W; Penner E; Grabner G
Arzneimittelforschung; 1977; 27(8):1599-604. PubMed ID: 334188
[TBL] [Abstract][Full Text] [Related]
2. A comparative trial of timolol and flutonidin as antihypertensive agents.
Salvadeo A; Segagni S; Villa G; Galli F; Piazza W; Bovio G
Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):78-84. PubMed ID: 7037661
[TBL] [Abstract][Full Text] [Related]
3. [Long-term treatment with a new antihypertensive drug: flutonidin].
Nicrosini F; Pasotti C
Minerva Med; 1983 May; 74(21):1297-300. PubMed ID: 6406947
[TBL] [Abstract][Full Text] [Related]
4. [A new antihypertensive imidazoline derivative (St 600, Fluoronidine): I. Haemodynamic investigations at rest and during exercise (author's transl)].
Djawan S; Mlezoch J; Niederberger M; Penner E; Grabner G
Wien Klin Wochenschr; 1976 Mar; 88(6):199-206. PubMed ID: 973381
[TBL] [Abstract][Full Text] [Related]
5. [Long-term experiences with moxonidine, a new antihypertensive agent].
Schwarz W; Kandziora J
Fortschr Med; 1990 Nov; 108(32):616-20. PubMed ID: 2262193
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of moxonidine in mild to moderate hypertension.
Jain S; Malhotra P; Kumari S; Varma S
J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474
[TBL] [Abstract][Full Text] [Related]
7. [A new antihypertensive agent used in a clinical setting].
Wetzels E; Raschig A; Kaiser HJ
Med Klin; 1980 Sep; 75(19):688-92. PubMed ID: 7001207
[TBL] [Abstract][Full Text] [Related]
8. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
Sharma AM; Wagner T; Marsalek P
J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive effect of prizidilol.
Jounela AJ; Honkala M; Huikuri H
Ann Clin Res; 1984; 16(3):176-80. PubMed ID: 6383185
[TBL] [Abstract][Full Text] [Related]
10. Guanfacine: a new centrally-acting antihypertensive agent.
Beevers DG; Bloxham CA; Walker JM
Pharmatherapeutica; 1981; 2(8):513-6. PubMed ID: 7019931
[TBL] [Abstract][Full Text] [Related]
11. Hypotensive action and side-effects of flutonidin in normal subjects. A double-blind controlled trial.
Sala P; Chierichetti SM; Ferrari P
Eur J Clin Pharmacol; 1979; 16(6):375-9. PubMed ID: 393519
[TBL] [Abstract][Full Text] [Related]
12. Effects of clonidin and chlorthalidone on blood pressure and glucose tolerance in hypertensive patients.
Sung PK; Samet P; Yeh BK
Curr Ther Res Clin Exp; 1971 May; 13(5):280-5. PubMed ID: 4998390
[No Abstract] [Full Text] [Related]
13. Blind trial with 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155) in essential hypertension. Effects on arterial blood pressures at rest and during exercise and on physical work capacity.
Koch G
Arzneimittelforschung; 1970 Dec; 20(12):1857-9. PubMed ID: 5537080
[No Abstract] [Full Text] [Related]
14. [Behavior of hemodynamic values of patients with hypertension during dichlorphenylamino-imidazoline therapy].
Pozenel H
Wien Klin Wochenschr; 1969 Mar; 81(11):187-92. PubMed ID: 4935483
[No Abstract] [Full Text] [Related]
15. [Administration of a new hypotensive agent 2-(2,6-dichlorphenylamino) imidazoline chlorhydrate in the treatment of essential arterial hypertension].
Borrello G
Clin Ter; 1971 Apr; 57(1):9-29. PubMed ID: 5090286
[No Abstract] [Full Text] [Related]
16. [Clinical and experimental study with the new blood pressure depressant 2-(2,6-dichlorphenylamino)-2-imidazole-hydrochloride].
Grabner G; Michalek P; Pokorny D; Vormittag E
Arzneimittelforschung; 1966 Sep; 16(9):1174-9. PubMed ID: 6014738
[No Abstract] [Full Text] [Related]
17. A three-phase clinical evaluation of prazosin.
Smith IS; Fernandes M; Kim KE; Swartz C; Onesti G
Postgrad Med; 1975 Nov; Spec No():53-60. PubMed ID: 1105485
[TBL] [Abstract][Full Text] [Related]
18. Benidipine hydrochloride--a new calcium-channel blocker of the dihydropyridine type. Pharmacokinetics, pharmacodynamics, tolerance and dose finding in mild to moderate hypertension.
Maier-Lenz H; Rode H; Lenau H; Thieme G; Wölke E; Kobayashi H; Kobayashi S; Oka T
Arzneimittelforschung; 1988 Nov; 38(11A):1757-63. PubMed ID: 3219156
[TBL] [Abstract][Full Text] [Related]
19. [Clinical experience with a new hypotensive drug: 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST-155)].
Langer-Costanzi M
Clin Ter; 1970 Dec; 55(5):419-31. PubMed ID: 5516107
[No Abstract] [Full Text] [Related]
20. Moxonidine: a new antiadrenergic antihypertensive agent.
Prichard BN; Graham BR; Owens CW
J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
